PTGX
Protagonist Therapeutics, Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Protagonist Therapeutics, Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.45%
vs ±11.8% implied · ×0.55
shaded = implied · ▲▼ = realized
No thesis.
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BlackRockBlackRockindex-like | $1.3B | 13.49% | +5.40% | |
| 2 | Farallon Capital ManagementFarallon | $778.2M | 8.31% | 0.00% | |
| 3 | RTW InvestmentsRTW | $620.4M | 6.62% | +0.04% | |
| 4 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $444.9M | 4.75% | +4.25% | |
| 5 | Wellington Management GroupWellington | $418.8M | 4.47% | −5.08% | |
| 6 | UBS GroupUBS | $416.7M | 4.45% | −34.35% | |
| 7 | State StreetState Streetindex-like | $407.2M | 4.35% | +6.57% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $349.8M | 3.73% | +1.69% | |
| 9 | Johnson & JohnsonJohnson & Johnson | $300.2M | 3.20% | 0.00% | |
| 10 | InvescoInvesco | $286.9M | 3.06% | +8.13% | |
| 11 | T. Rowe Price AssociatesT. Rowe Price | $263.5M | 2.81% | +29.07% | |
| 12 | Jupiter TopcoJupiter Topco | $261.0M | 2.79% | — | |
| 13 | Geode Capital ManagementGeodeindex-like | $213.5M | 2.28% | +4.30% | |
| 14 | Woodline PartnersWoodline Partners | $173.3M | 1.85% | 0.00% | |
| 15 | Bank of AmericaBank of America | $162.4M | 1.73% | +2.24% | |
| 16 | Jennison AssociatesJennison | $141.2M | 1.51% | +7.43% | |
| 17 | Perceptive AdvisorsPerceptive | $120.4M | 1.28% | −20.23% | |
| 18 | ADAR1 Capital ManagementADAR1 | $117.8M | 1.26% | −3.35% | |
| 19 | Morgan StanleyMorgan Stanley | $111.1M | 1.19% | −11.02% | |
| 20 | Alyeska Investment GroupAlyeska Investment | $109.0M | 1.16% | +49.92% | |
| 21 | Hood River Capital ManagementHood River | $108.2M | 1.16% | +6.45% | |
| 22 | Goldman Sachs GroupGoldman Sachs | $99.6M | 1.06% | +4.35% | |
| 23 | Driehaus Capital ManagementDriehaus | $89.6M | 0.96% | +1.40% | |
| 24 | Clearbridge InvestmentsClearbridge | $88.9M | 0.95% | +16.65% | |
| 25 | FMRFMR | $82.4M | 0.88% | +1.54% |
345 managers report $9.4B of Protagonist Therapeutics on form 13F for the quarter ended Jun 30 '26. 26 of them hold 80% of it; BlackRock is largest at 13.49%.
Linked news
Expected move
Inputs8Q avg ±3.1%·×1.81·rich
straddle ±7.7%
spot 144.85exp Nov 20ATM strike 145ATM straddle 13.20IV 48%
Protagonist Therapeutics, Inc
144.19
−0.15 · −0.11%
post 144.17 −0.01%